|1.||Jenner, Peter: 8 articles (01/2015 - 09/2002)|
|2.||Lees, Andrew J: 6 articles (02/2013 - 09/2002)|
|3.||Oertel, Wolfgang H: 5 articles (01/2007 - 05/2002)|
|4.||Jenner, P: 5 articles (01/2005 - 04/2000)|
|5.||Trenkwalder, Claudia: 4 articles (12/2010 - 09/2002)|
|6.||Samadi, Pershia: 4 articles (04/2010 - 12/2003)|
|7.||Pivonello, Rosario: 4 articles (01/2010 - 06/2002)|
|8.||Colao, Annamaria: 4 articles (01/2010 - 06/2002)|
|9.||Lang, Anthony E: 4 articles (02/2007 - 03/2002)|
|10.||Bédard, Paul J: 4 articles (06/2005 - 12/2003)|
|1.||Parkinson Disease (Parkinson's Disease)
01/01/1987 - "PHNO differs from other dopaminergic drugs and may be useful in the treatment of Parkinson's disease."
01/01/2006 - "Although it is an undeniable fact that dopaminergic therapy has greatly improved the quality of life and prognosis of patients with Parkinson's disease, various and serious adverse events correlated to dopaminergic drugs are not uncommon. "
05/01/2014 - "The objectives of the present study were to assess the effects of dopaminergic drugs on the postural balance of Parkinson disease (PD) patients and to ascertain whether their sway is greater along the mediolateral or the anteroposterior axis. "
04/01/2013 - "Eighteen Parkinson's disease patients who had never been treated before with dopaminergic drugs (male = 9, female = 9, age: 68.39 ± 1.89, mean ± standard error) and 18 healthy subjects (male = 9, female = 9, age: 67.22 ± 1.98) were recruited for this study. "
08/01/2003 - "Electrophysiological studies in rats, monkeys and patients with Parkinson's disease have shown that power and coherence of low frequency oscillations in CST systems can be profoundly modulated by dopaminergic drugs. "
04/01/2000 - "However, a variety of therapeutic strategies primarily related to the use of non-dopaminergic agents may be able to prevent dyskinesia from occurring, and the actions of neurotropic factors, such as glial-derived neurotropic factor, may be effective in reversing established involuntary movements."
05/01/2012 - "Improvement in motor fluctuations is linked to the direct effect of stimulation on the sensory-motor subthalamic territory, while improvement in dyskinesias is mainly explained by an indirect effect related to the decrease in dopaminergic drugs. "
08/01/2002 - "Mean dosage of dopaminergic drugs was reduced, but force overflow and dyskinesias were equally improved in 2 patients without a reduction. "
01/01/2015 - "Non-dopaminergic agents are also being investigated for the treatment of dyskinesia and for the relief of non-motor symptoms. "
06/15/2013 - "Depression, cognitive impairment, coping strategies, dyskinesia, gait disorders and complications of dopaminergic drugs are the variables that most affect health-related quality of life. "
|3.||Restless Legs Syndrome (Restless Legs)
01/01/2007 - "Dopaminergic agents are the best-studied agents and are considered first-line treatment of restless legs syndrome (RLS). "
09/01/2001 - "Dopaminergic agents are highly effective in treating restless legs syndrome, but side effects can be problematic. "
02/01/2012 - "Dopaminergic drugs are the mainstay of treatment for restless legs syndrome (RLS). "
12/01/2010 - "Numerous randomised controlled trials have proved the efficacy of dopaminergic and non-dopaminergic drugs in the treatment of restless legs syndrome (RLS). "
10/01/2010 - "Dopaminergic agents are the first-line treatment of restless legs syndrome (RLS), and have been used for the treatment of this disorder since the 1980s. "
09/01/2004 - "The only important predictors of improvement in UPDRS part III motor scores were the baseline response to dopaminergic drugs (p = 0.015) and the presence of tremor (p = 0.027). "
02/26/2002 - "Although all dopaminergic drugs are effective in reducing tremor, no single drug has been shown to be clearly superior in the treatment of tremor. "
03/01/1999 - "We found that anticholinergic and dopaminergic agents are both effective in reducing tremor in IPD, and there was no evidence for a selective anticholinergic responsiveness of parkinsonian tremor. "
11/01/2003 - "Dopaminergic studies may have a limited clinical role in the diagnosis of patients who have symptoms that suggestive of PD yet do not respond to typical dopaminergic drugs, such as patients who have vascular parkinsonism or ET with mild resting tremor who may have normal dopaminergic innervation. "
09/01/2004 - "All these may be used as initial therapy and delay the use of dopaminergic drugs, or can be added later to reduce specific symptoms (tremor or dyskinesias). "
12/01/2001 - "The treatment of hyperprolactinemia has greatly benefited from the generation of progressively more effective and selective dopaminergic drugs."
08/01/1992 - "The effect of two dopaminergic drugs on menstrual function and psychological state in hyperprolactinemia."
07/01/1991 - "Lastly, particular aspects are taken into consideration, such as the relationship between hyperprolactinemia and pregnancy, in the light of the most recent findings on the natural evolution of prolactinemia and the possibility of treatment using dopaminergic drugs."
01/01/1983 - "[Dopaminergic agents in the treatment of hyperprolactinemia]."
03/01/1998 - "Increased prevalence of Helicobacter pylori infection in females treated with dopaminergic drugs for hyperprolactinaemia."
|1.||Levodopa (L Dopa)
|5.||Antidepressive Agents (Antidepressants)
|6.||Cholinergic Agents (Cholinergics)
|10.||1- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)
|4.||Drug Therapy (Chemotherapy)
|5.||Deep Brain Stimulation